Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Stem Cell Institute Cayman utilizes IRB-approved protocols for MSC therapy to treat degenerative disc disease, building on 21+ years of clinical experience from its Panama facility; peer-reviewed trials show significant improvements in pain and function in DDD with no serious adverse events reported over 55,000+ administrations[1][7][15].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Stem Cell Institute Cayman.